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The subject of systemic delivery of biopharmaceuticals has been discussed in some occasions 
in Journal of Pharmacy and Bioallied Sciences, which is now in its 11th issue. The last decades 
have witnessed a strong biotechnological progress, making available many biopharmaceuticals 
with great therapeutic potential, in many cases promising an undisputed place alongside other 
established therapies. The meaning of biopharmaceuticals is sometimes misleading but, 
rigorously, this word refers to therapeutic molecules that are biological in nature and 
manufactured using biotechnology. In this sense, a considerable wide variety of 
macromolecules is included in this group, from proteins and peptides, to antigens and nucleic 
acids. Their administration is extremely challenging because of biopharmaceutical and 
physicochemical limitations, requiring circumventing enzymatic degradation and reducing 
immune reactions, while ensuring molecular stability and permeability. Parenteral administration 
appears in this context as an obvious option, as it overcomes some of the referred issues. 
Actually, to date, the vast majority of marketed biopharmaceuticals is administered by direct 
injection, usually through intravenous, subcutaneous or intramuscular route. However, the 
associated cost and patient discomfort, have turned the research efforts of both industrial and 
academic partners towards alternative possibilities that increase patient compliance.  
The compelling need to address the issues mentioned above has prompted the design of a 
number of strategies that permit needle-free administration, conjugating the identification of 
alternative routes of administration with the necessary development of adequate drug delivery 
carriers. Mucosal routes have, thus, been proposed to replace parenteral routes, as mucosal 
administration might be envisaged to provide a non-invasive systemic pathway. Oral, buccal, 
nasal, pulmonary, transdermal and vaginal routes are all accepted for systemic 
biopharmaceutical delivery. However, poor patient acceptability of certain routes like vaginal, 
reserves their use for local effect only. Nevertheless, the oral, nasal, pulmonary and 
transdermal routes are taking the forefront of alternative drug delivery, with some technologies 
already available commercially. BiphasixTM technology (Helix BioPharma) addresses 
transdermal delivery using liposomes, as do ImuXen® technology (Lipoxen) for oral delivery of 
DNA and vaccines and AERx® technology (Aradigm Corporation) for pulmonary delivery. Still in 
pulmonary delivery, Technosphere® technology (Mannkind Corporation) comprises insulin-
loaded dry powder microspheres, which are in phase III clinical trials. Importantly, a dry powder 
formulation of insulin (Exubera®) was previously marketed by Pfizer, but was withdrawn from 
market by the company, allegedly because of reduced patient adherence to the novel 
therapeutic strategy. As can be seen, mucosal administration of biopharmaceuticals is 
inseparable from the task of designing suitable drug carriers. In this sense, as it was stated in a 
previous Editorial of this journal (Vol. 2, Issue 2, 2010), in many cases nanomedicines seem to 
have taken advantage, with many reports providing the possibility to make stable effective drugs 
from unstable biopharmaceuticals. In any case, the carrier is required to maintain the native 
structure and the biological activity of the encapsulated biopharmaceutical during preparation, 
delivery and storage. 
With such technologies already in the market, and so many others being developed worldwide 
by academic and industrial researchers, it seems justified to state that the future of 
biopharmaceutical administration will be progressively shifted from injectable preparations to 
more user-friendly formulations, with the striking advantage of mucosal routes relying on their 
non-invasiveness. 
